Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(4.26)
# 1,377
Out of 4,457 analysts
76
Total ratings
49.2%
Success rate
18.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PMN ProMIS Neurosciences | Initiated Coverage: Buy | $40 | $10.75 | +269.77% | 1 | Jun 29, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $100 | $43.15 | +131.75% | 10 | Jun 4, 2026 | |
| AXSM Axsome Therapeutics | Maintained: Buy | $220 → $272 | $241.12 | +12.81% | 5 | May 4, 2026 | |
| ALEC Alector | Upgraded: Buy | n/a | $2.08 | - | 3 | Apr 15, 2026 | |
| RZLT Rezolute | Maintained: Hold | n/a | $5.10 | - | 6 | Mar 25, 2026 | |
| ALKS Alkermes | Maintained: Buy | $43 | $52.53 | -18.14% | 1 | Mar 11, 2026 | |
| NVAX Novavax | Maintained: Buy | $18 | $9.36 | +92.31% | 2 | Jan 13, 2026 | |
| CRVO CervoMed | Initiated Coverage: Buy | n/a | $3.15 | - | 1 | Dec 18, 2025 | |
| HELP Cybin | Reiterated: Buy | n/a | $6.88 | - | 1 | Oct 15, 2025 | |
| DNTH Dianthus Therapeutics | Reiterated: Buy | n/a | $95.68 | - | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.88 | - | 5 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.4198 | - | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $69.18 | - | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $6.82 | - | 7 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.57 | n/a | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $1.15 | n/a | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $3.58 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $3.82 | n/a | 4 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $2.77 | n/a | 3 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $21.04 | n/a | 3 | Jun 23, 2023 |
ProMIS Neurosciences
Jun 29, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $10.75
Upside: +269.77%
Vera Therapeutics
Jun 4, 2026
Maintained: Buy
Price Target: $100
Current: $43.15
Upside: +131.75%
Axsome Therapeutics
May 4, 2026
Maintained: Buy
Price Target: $220 → $272
Current: $241.12
Upside: +12.81%
Alector
Apr 15, 2026
Upgraded: Buy
Price Target: n/a
Current: $2.08
Upside: -
Rezolute
Mar 25, 2026
Maintained: Hold
Price Target: n/a
Current: $5.10
Upside: -
Alkermes
Mar 11, 2026
Maintained: Buy
Price Target: $43
Current: $52.53
Upside: -18.14%
Novavax
Jan 13, 2026
Maintained: Buy
Price Target: $18
Current: $9.36
Upside: +92.31%
CervoMed
Dec 18, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $3.15
Upside: -
Cybin
Oct 15, 2025
Reiterated: Buy
Price Target: n/a
Current: $6.88
Upside: -
Dianthus Therapeutics
Aug 22, 2025
Reiterated: Buy
Price Target: n/a
Current: $95.68
Upside: -
Jul 10, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.88
Upside: -
Jul 7, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.4198
Upside: -
Jul 2, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $69.18
Upside: -
Jul 1, 2025
Reiterated: Buy
Price Target: n/a
Current: $6.82
Upside: -
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $5.57
Upside: n/a
Mar 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $1.15
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $3.58
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $34
Current: $3.82
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $13
Current: $2.77
Upside: n/a
Jun 23, 2023
Rated: Hold
Price Target: n/a
Current: $21.04
Upside: n/a